Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Epivax Inc. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently faces 1 pending office action. This action is assigned to 1 distinct examiner, TARA L MARTINEZ. Because the portfolio involves 1 distinct art unit, the prosecution efforts are concentrated within a specific regulatory environment. This focus allows for a deep understanding of the specific examination standards applied by that unit to biotechnology inventions.
TARA L MARTINEZ serves as the busiest examiner for the company, with 1 pending office action under review. This individual handles the total volume of the company's current pending office actions. For a portfolio with 1 distinct examiner and 1 distinct art unit, the prosecution strategy is currently focused on a specific point of contact at the patent office. This concentration means that the outcome of the 1 pending office action will significantly impact the immediate status of the company's biotechnology filings. The presence of only 1 distinct art unit suggests a narrow technological focus for the current active applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTINEZ, TARA L | 1 | 62.6% | +65.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044876 | RETRO - INVERSO REGULATORY T CELL EPITOPES | MARTINEZ, TARA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044876 | RETRO - INVERSO REGULATORY T CELL EPITOPES | MARTINEZ, TARA L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044876 | RETRO - INVERSO REGULATORY T CELL EPITOPES | MARTINEZ, TARA L | 1654 | §101§102§112DP | Non-Final OA | — | Pending | Mar 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial